Iqbal Farwah, Gratch Yarden S, Szaraz Peter, Librach Clifford L
Create Fertility Centre; Department of Physiology, University of Toronto;
Create Fertility Centre.
J Vis Exp. 2017 Sep 18(127):56083. doi: 10.3791/56083.
Angiogenesis is a complex, highly regulated process responsible for providing and maintaining adequate tissue perfusion. Insufficient vasculature maintenance and pathological malformations can result in severe ischemic diseases, while overly abundant vascular development is associated with cancer and inflammatory disorders. A promising form of pro-angiogenic therapy is the use of angiogenic cell sources, which can provide regulatory factors as well as physical support for newly developing vasculature. Mesenchymal Stromal Cells (MSCs) are extensively investigated candidates for vascular regeneration due to their paracrine effects and their ability to detect and home to ischemic or inflamed tissues. In particular, first trimester human umbilical cord perivascular cells (FTM HUCPVCs) are a highly promising candidate due to their pericyte-like properties, high proliferative and multilineage potential, immune-privileged properties, and robust paracrine profile. To effectively evaluate potentially angiogenic regenerative cells, it is a requisite to test them in reliable and "translatable" pre-clinical assays. The aortic ring assay is an ex vivo angiogenesis model that allows for easy quantification of tubular endothelial structures, provides accessory supportive cells and extracellular matrix (ECM) from the host, excludes inflammatory components, and is fast and inexpensive to set up. This is advantageous when compared to in vivo models (e.g., corneal assay, Matrigel plug assay); the aortic ring assay can track the administered cells and observe intercellular interactions while avoiding xeno-immune rejection. We present a protocol for a novel application of the aortic ring assay, which includes human MSCs in co-cultures with developing rat aortic endothelial networks. This assay allows for the analysis of the MSC contribution to tube formation and development through physical pericyte-like interactions and of their potency for actively migrating to sites of angiogenesis, and for evaluating their ability to perform and mediate ECM processing. This protocol provides further information on changes in MSC phenotype and gene expression following co-culture.
血管生成是一个复杂且高度受调控的过程,负责提供和维持充足的组织灌注。血管维持不足和病理性畸形可导致严重的缺血性疾病,而血管过度发育则与癌症和炎症性疾病相关。一种有前景的促血管生成治疗形式是使用血管生成细胞来源,其可为新形成的血管提供调节因子以及物理支持。间充质基质细胞(MSCs)因其旁分泌作用以及检测和归巢至缺血或炎症组织的能力而被广泛研究作为血管再生的候选细胞。特别是,孕早期人脐带血管周围细胞(FTM HUCPVCs)因其类周细胞特性、高增殖和多系分化潜能、免疫特权特性以及强大的旁分泌特征而成为极具潜力的候选细胞。为了有效评估潜在的血管生成再生细胞,在可靠且“可转化”的临床前试验中对其进行测试是必要的。主动脉环试验是一种体外血管生成模型,它能够轻松定量管状内皮结构,提供来自宿主的辅助支持细胞和细胞外基质(ECM),排除炎症成分,并且设置快速且成本低廉。与体内模型(如角膜试验、基质胶栓塞试验)相比,这具有优势;主动脉环试验可以追踪所施用的细胞并观察细胞间相互作用,同时避免异种免疫排斥。我们提出了一种主动脉环试验新应用的方案,该方案包括将人MSCs与发育中的大鼠主动脉内皮网络共培养。该试验允许通过类周细胞样的物理相互作用分析MSCs对血管形成和发育的贡献,以及它们主动迁移至血管生成部位的能力,并评估它们进行和介导ECM加工的能力。该方案提供了关于共培养后MSCs表型和基因表达变化的进一步信息。